$42.54
+0.56(1.33%)
Mkt Cap $4.5B
$32.15
$90.32
52-Week Range
At a Glance
AI-generated8-K
Corcept Therapeutics Incorporated announced on March 25, 2026, that the U.S. Food and Drug Administration approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received one to three prior systemic treatment regimens, at least one including bevacizumab. Approval based on ROSELLA trial demonstrating 35% reduction in death risk and 30% reduction in progression risk.$4.5B
Market Cap
$780M
Revenue
$101M
Net Income
Employees500
Fundamentals
How The Business Makes Money
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001088856
ISINUS2183521028
CUSIP218352102
Phone650 327 3270
Address149 Commonwealth Drive, Menlo Park, CA, 94025, US
SEC EDGAR